1 Prostate Anatomy and Causative Theories, Pathophysiology, and Natural History of Benign Prostatic Hyperplasia.- 2 The Definition of Benign Prostatic Hyperplasia: Epidemiology and Prevalence.- 3 Pathophysiology, Diagnosis, and Treatment of the Postobstructive Diuresis.- 4 Urodynamics and the Evaluation of Male Lower Urinary Tract Symptoms.- 5 ?-Adrenergic Antagonists in the Treatment of Benign Prostatic Hypertrophy-Associated Lower Urinary Tract Symptoms.- 6 5?-Reductase Inhibitors.- 7 Transurethral Needle Ablation of the Prostate.- 8 Transurethral Microwave Thermotherapy.- 9 Transurethral Incision of the Prostate.- 10 Interstitial Laser Coagulation and High-Intensity Focused Ultrasound for the Treatment of Benign Prostatic Hyperplasia.- 11 Transurethral Resection of the Prostate.- 12 Transurethral Vaporization of the Prostate.- 13 Treatment of Benign Prostatic Hyperplasia with Ethanol Injections, Water-Induced Thermotherapy, and Prostatic Urethral Luminal Stents.- 14 Suprapubic Transvesical Prostatectomy and Simple Perineal Prostatectomy for the Treatment of Benign Prostatic Hyperplasia.

Numerous recent advances in the medications and technologies available to treat benign prostatic hyperplasia (BPH) raise many questions for practicing urologists seeking optimal therapies for their patients. In Management of Benign Prostatic Hypertrophy, a panel of internationally recognized expert clinicians and investigators in urology review the new treatments in the light of established urologic principles and tradition. The authors concisely evaluate the latest minimally invasive therapies, as well as time-tested surgical treatments, and review the medical therapies for BPH, namely a-adrenergic antagonists, 5a-reductase inhibitors, and their therapeutic combinations. Additional chapters examine the pathophysiology and natural history of BPH, its epidemiology, and the urodynamic evaluation of lower urinary tract symptoms, with special attention given to a more current understanding and treatment of postobstructive diuresis, a significant medical complication and frequent source of urologic consultation. Grounded in the principles and hallmarks of urology, Management of Benign Prostatic Hypertrophy satisfies the needs of practicing urologists seeking a concise up-to-date interpretation and analysis of the many new therapies available for the treatment of BPH.

GPSR Compliance The European Union's (EU) General Product Safety Regulation (GPSR) is a set of rules that requires consumer products to be safe and our obligations to ensure this. If you have any concerns about our products you can contact us on ProductSafety@springernature.com. In case Publisher is established outside the EU, the EU authorized representative is: Springer Nature Customer Service Center GmbH Europaplatz 3 69115 Heidelberg, Germany ProductSafety@springernature.com